Literature DB >> 16441232

Adipose targets for obesity drug development.

Olivier Boss1, Nils Bergenhem.   

Abstract

The prevalence of obesity is increasing rapidly in most parts of the world and effective therapeutic drugs are urgently needed. The discovery of leptin in 1994 initiated a new understanding of adipose tissue function, and adipose tissue is now known to not only store and release fatty acids, but also to produce a wealth of factors that have an impact on the regulation of body weight and blood glucose homeostasis. Also, adipocytes express proteins that engage signalling pathways playing important roles in fuel substrate and energy metabolism. These proteins constitute a diverse array of adipose target candidates for the development of drugs to treat obesity. Some of these potential targets have been validated and are now in drug development stages, providing hope that the current obesity epidemic can be addressed by effective drug treatments in the near future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441232     DOI: 10.1517/14728222.10.1.119

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  4 in total

Review 1.  The MC4 receptor and control of appetite.

Authors:  R A H Adan; B Tiesjema; J J G Hillebrand; S E la Fleur; M J H Kas; M de Krom
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

2.  Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation.

Authors:  Andrea Mencarelli; Eleonora Distrutti; Barbara Renga; Claudio D'Amore; Sabrina Cipriani; Giuseppe Palladino; Annibale Donini; Patrizia Ricci; Stefano Fiorucci
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

3.  Theophylline Extracted from Fu Brick Tea Affects the Metabolism of Preadipocytes and Body Fat in Mice as a Pancreatic Lipase Inhibitor.

Authors:  Tian-Tian Liu; Xiao-Tian Liu; Gui-Li Huang; Long Liu; Qing-Xi Chen; Qin Wang
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

4.  Modulation of PPAR-γ by Nutraceutics as Complementary Treatment for Obesity-Related Disorders and Inflammatory Diseases.

Authors:  D Ortuño Sahagún; A L Márquez-Aguirre; S Quintero-Fabián; R I López-Roa; A E Rojas-Mayorquín
Journal:  PPAR Res       Date:  2012-11-28       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.